TY - JOUR
T1 - High-Dose-Rate Interstitial Brachytherapy (Interventional Radiotherapy) for Conjunctival Melanoma with Orbital Extension
AU - Pagliara, Monica Maria
AU - Tagliaferri, Luca
AU - Savino, Gustavo
AU - Fionda, Bruno
AU - D'Aviero, Andrea
AU - Lanza, Angela
AU - Lanza, Gaetano Antonio
AU - Lancellotta, Valentina
AU - Midena, Giulia
AU - Gambacorta, Maria Antonietta
AU - Blasi, Maria Antonietta
PY - 2021
Y1 - 2021
N2 - Purpose: To evaluate local control and functional and cosmetic outcomes of postoperative high-dose-rate interventional radiotherapy (HDR-IRT) in patients affected by conjunctival melanoma with orbit invasion. Methods: A retrospective study was conducted in 2 patients affected by conjunctival melanoma infiltrating the orbit, treated with surgical excision and HDR-IRT. The treatment procedures consisted of surgical excision of the orbital infiltrating nodule followed, 1 month after surgery, by adjuvant HDR-IRT. A target dose of 34 Gy was delivered in 10 twice-a-day fractions over 5 consecutive days. Data analysis included local tumor control and metastatic rate, acute and late toxicity, functional and aesthetic results. Results: In both patients, treatment was well tolerated, and there was no orbital recurrence at a median follow-up of 37-40 months. There was an excellent functional outcome, without no significant acute or late side effects. Conclusions: HDR-IRT could be considered a promising, feasible, successful, and well-tolerated option for selected patients affected by ocular tumors with orbital invasion.
AB - Purpose: To evaluate local control and functional and cosmetic outcomes of postoperative high-dose-rate interventional radiotherapy (HDR-IRT) in patients affected by conjunctival melanoma with orbit invasion. Methods: A retrospective study was conducted in 2 patients affected by conjunctival melanoma infiltrating the orbit, treated with surgical excision and HDR-IRT. The treatment procedures consisted of surgical excision of the orbital infiltrating nodule followed, 1 month after surgery, by adjuvant HDR-IRT. A target dose of 34 Gy was delivered in 10 twice-a-day fractions over 5 consecutive days. Data analysis included local tumor control and metastatic rate, acute and late toxicity, functional and aesthetic results. Results: In both patients, treatment was well tolerated, and there was no orbital recurrence at a median follow-up of 37-40 months. There was an excellent functional outcome, without no significant acute or late side effects. Conclusions: HDR-IRT could be considered a promising, feasible, successful, and well-tolerated option for selected patients affected by ocular tumors with orbital invasion.
KW - Brachytherapy
KW - Conjunctival melanoma
KW - Ocular oncology
KW - Ocular tumors
KW - Ophthalmic oncology
KW - Brachytherapy
KW - Conjunctival melanoma
KW - Ocular oncology
KW - Ocular tumors
KW - Ophthalmic oncology
UR - http://hdl.handle.net/10807/184746
U2 - 10.1159/000512344
DO - 10.1159/000512344
M3 - Article
SN - 2296-4681
VL - 7
SP - 199
EP - 205
JO - Ocular Oncology and Pathology
JF - Ocular Oncology and Pathology
ER -